Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The dual-specificity tyrosine-regulated kinases (DYRKs) are a family of protein kinases within the CMGC group, characterized by the ability to phosphorylate substrates on serine/threonine as well as tyrosine residues. Humans encode five known DYRK proteins (DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4), all sharing a highly conserved catalytic core and structural domains specific to their class. DYRK kinases are pleiotropic regulators involved in critical cellular processes, including cell cycle regulation, developmental signaling, gene expression, DNA damage response, and the formation of specialized cellular structures such as the primary cilium. Dysregulation and mutation of these kinases are implicated in various diseases, notably some cancers, neurodevelopmental disorders, and other human pathologies. DYRKs are considered promising but challenging drug targets due to their central roles and the risk of off-target effects.
Inhibition of kinase activity (ATP-competitive inhibition), regulation of substrate phosphorylation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dual-specificity tyrosine-regulated kinase (DYRK).